Literature DB >> 6142994

Severe pulmonary hypersensitivity associated with passive transfusion of a neutrophil-specific antibody.

R Yomtovian, W Kline, C Press, M Clay, H Engman, D Hammerschmidt, J McCullough.   

Abstract

A life-threatening pulmonary hypersensitivity reaction accompanied by profound leucopenia and transient hypocomplementaemia developed in a 73-year-old man after repair of an abdominal aortic aneurysm. A neutrophil-specific antibody, anti-NA2) was demonstrated by granulocyte immunofluorescence and microagglutination in one of the transfused donor units. In addition, activated complement component C5a was generated in vitro by incubation of the patient's serum with the aortic graft material. This severe clinical reaction may have resulted from the interaction of the transfused anti-NA2 antibody with complement activation induced by the aortic graft material.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6142994     DOI: 10.1016/s0140-6736(84)90124-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  19 in total

1.  Transfusion-Related Acute Lung Injury: Incidence, Pathogenesis and the Role of Multicomponent Apheresis in Its Prevention.

Authors:  Mark A Popovsky
Journal:  Transfus Med Hemother       Date:  2008-03-10       Impact factor: 3.747

Review 2.  Therapeutic options for transfusion related acute lung injury; the potential of the G2A receptor.

Authors:  Michael A Ellison; Daniel R Ambruso; Christopher C Silliman
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

3.  Transfusion-related acute lung injury.

Authors:  Hava Üsküdar Teke; Orhan Behret; Deniz Teke
Journal:  Indian J Hematol Blood Transfus       Date:  2012-09-18       Impact factor: 0.900

4.  Identification of lipids that accumulate during the routine storage of prestorage leukoreduced red blood cells and cause acute lung injury.

Authors:  Christopher C Silliman; Ernest E Moore; Marguerite R Kelher; Samina Y Khan; Lauren Gellar; David J Elzi
Journal:  Transfusion       Date:  2011-05-26       Impact factor: 3.157

5.  Donor antibodies to HNA-3a implicated in TRALI reactions prime neutrophils and cause PMN-mediated damage to human pulmonary microvascular endothelial cells in a two-event in vitro model.

Authors:  Christopher C Silliman; Brian R Curtis; Patricia M Kopko; Samina Y Khan; Marguerite R Kelher; Randy M Schuller; Baindu Sannoh; Daniel R Ambruso
Journal:  Blood       Date:  2006-10-12       Impact factor: 22.113

Review 6.  Experimental models of transfusion-related acute lung injury.

Authors:  Brian M Gilliss; Mark R Looney
Journal:  Transfus Med Rev       Date:  2011-01

7.  Prospective study on the clinical course and outcomes in transfusion-related acute lung injury*.

Authors:  Mark R Looney; Nareg Roubinian; Ognjen Gajic; Michael A Gropper; Rolf D Hubmayr; Clifford A Lowell; Peter Bacchetti; Gregory Wilson; Monique Koenigsberg; Deanna C Lee; Ping Wu; Barbara Grimes; Philip J Norris; Edward L Murphy; Manish J Gandhi; Jeffrey L Winters; David C Mair; Randy M Schuller; Nora V Hirschler; Rosa Sanchez Rosen; Michael A Matthay; Pearl Toy
Journal:  Crit Care Med       Date:  2014-07       Impact factor: 7.598

Review 8.  Transfusion-related acute lung injury (TRALI): current concepts and misconceptions.

Authors:  Christopher C Silliman; Yoke Lin Fung; J Bradley Ball; Samina Y Khan
Journal:  Blood Rev       Date:  2009-08-20       Impact factor: 8.250

9.  Plasma from stored packed red blood cells and MHC class I antibodies causes acute lung injury in a 2-event in vivo rat model.

Authors:  Marguerite R Kelher; Tomhiko Masuno; Ernest E Moore; Sagar Damle; Xianzhong Meng; Yong Song; Xiayuan Liang; Jerry Niedzinski; Steven S Geier; Samina Y Khan; Fabia Gamboni-Robertson; Christopher C Silliman
Journal:  Blood       Date:  2009-01-08       Impact factor: 22.113

10.  TRALI--definition, mechanisms, incidence and clinical relevance.

Authors:  Pearl Toy; Clifford Lowell
Journal:  Best Pract Res Clin Anaesthesiol       Date:  2007-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.